25 results about "Chyle" patented technology

The invention discloses kluyveromyces marxianus KUST3801 for preventing and treating celiac disease, application of the kluyveromyces marxianus KUST3801 and a fruit and vegetable fermented beverage. The preservation number is CGMCC NO. 32767; the Kluyveromyces marxianus strain is classified and named as Kluyveromyces marxianus, and the Kluyveromyces marxianus strain is named as Kluyveromyces marxianus. The strain can be used for effectively preventing and treating celiac disease by protecting intestinal mucosa and intestinal barrier, regulating immunity and relieving inflammation. In addition, in the preparation of the fermented fruit and vegetable juice beverage, the aroma of the beverage can be improved, and the antioxidant activity is enhanced.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

This invention belongs to the field of medical device technology and discloses a blood bag with built-in tubing and its compression separation method for separating plasma with chylous stratification after high-speed centrifugation. The bag includes a bag body and a tubular assembly disposed on the end face opposite to the side of the bag body that bears the centrifugal force during centrifugation. The tubular assembly includes a separation tube extending into the bag body with its opening always located at the bottom of the bag body on the opposite side of the fixed end. The separation tube has a higher hardness than the bag body. The method involves removing and fixing the bag body after centrifugation, where the upper chyle layer and lower plasma layer are separated. Then, the plasma is pushed out from both sides of the larger area of ​​the bag body by manual squeezing or external squeezing. This invention has a simple structure and low cost, but can avoid the influence of centrifugation while recovering and reusing plasma with high chyle content that is difficult to utilize.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

The invention discloses a blood chyle degree detection reference and a preparation method thereof. The reference comprises the following components: triglyceride, cholesteryl ester, free cholesterol, phosphatidylcholine, bovine serum albumin, a buffer solution and an auxiliary agent. The blood chyle degree detection reference product provided by the invention can be stably stored, is low in cost, can be used for instrument calibration, can be used for judging and grading clinical plasma chyle degree and the like, and can unify detection standards and eliminate artificial interference; based on the blood chyle degree detection reference product provided by the invention, detection can be realized by utilizing image gray calculation, and compared with manual visual inspection, the detection accuracy is greatly improved.

The invention belongs to the technical field of medical instruments, and discloses a blood bag with a built-in pipeline and an extrusion separation method of the blood bag, the blood bag is used for separating plasma with chyle layering after high-speed centrifugation, and the blood bag comprises a bag body and a pipe body group arranged on the end face of the side opposite to the end face of the side, bearing centrifugal force, of the bag body during centrifugation. The tube body group comprises a separation tube which extends into the bag body, a tube opening of the separation tube is always positioned at the inner bottom of one side opposite to the fixed end in the bag body, and the hardness of the separation tube is greater than that of the bag body. The method comprises the following steps: taking out and fixing a bag body of an upper chyle layer and a lower plasma layer after centrifugation, and then pushing plasma to be discharged from a separation tube from two large-area sides of the bag body in a manner of manual extrusion by hands or extrusion by an external extrusion structure. The device is simple in structure and relatively low in cost, and can be used for recycling plasma with high chyle content which is difficult to use while avoiding centrifugal influence.

The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVII).

The invention relates to the field of pharmaceutical preparations and pharmaceutical chemistry, belongs to the technical field of oral delivery of antitumor drugs, and particularly relates to an abiraterone lipophilic prodrug and application thereof. The prodrug meets the following general formula: AB-O-C (= O)-(CH2) m-S-S-(CH2) m-C (= O)-O-R, the prodrug significantly improves the fat solubility and intestinal absorption capacity of abiraterone, can be absorbed through a chylomicron-mediated lymph transport pathway, and releases a parent drug in a tumor cell high-reducibility environment. The SNEDDS preparation containing the prodrug can form a particle size of 1t in vivo; the O / W type nano emulsion droplet with the size of 100 nm can significantly improve the oral bioavailability of abiraterone and inhibit the growth of prostatic cancer tumors, and has a good application prospect.

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

The present application belongs to the technical field of enteral nutrition preparation, and particularly relates to an enteral nutrition supplement for hyperlipidemia, a preparation method and application thereof. The enteral nutrition supplement comprises the following raw materials: medium-chain triglyceride, camellia chrysanthemum culture and cherry blossom polyphenol, and further comprises protein 15-25 parts, carbohydrate 40-50 parts, compound vitamin 0.01-0.05 parts and mineral 1-5 parts. The prepared enteral nutrition supplement is composed of a fat system completely formed by medium-chain fatty acid ester, and the blood fat is improved by synergistic effect of the camellia chrysanthemum culture and the cherry blossom polyphenol, so as to solve the application problem of traditional long-chain fat nutrition support under specific pathological conditions such as fatty liver, chylous fistula and chronic pancreatitis.

An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.

The invention provides a chyloplasma recovery treatment method, which comprises the following steps: modifying kaolin by using alkali and acid substances in sequence, then filtering the chyloplasma by using the modified kaolin and diatomite in sequence, and adopting a filter with a multi-layer gradient structure when the chyloplasma is treated by using the diatomite. According to the technical scheme, cholesterol and triglyceride in chylous plasma are remarkably reduced, and a plasma product with low turbidity is obtained.

The present application relates to the technical field of pharmaceutical preparation, and in particular to an abiraterone acetate enteric microcapsule and a preparation method thereof. The present application uses an emulsion diffusion method to prepare abiraterone acetate nanocapsules, then uses an enteric material to load the abiraterone acetate nanocapsules, and finally uses a spray drying technology to prepare abiraterone acetate oral enteric microcapsules. Through pharmacokinetic tests of a rat chylomicron blocking model, it is verified that the abiraterone acetate enteric microcapsules prepared by the present application are absorbed by the lymphatic pathway in the small intestine, so it is proved that the present application can enhance the permeability and solubility of abiraterone acetate in the body, improve the oral bioavailability thereof in the body, the preparation method is simple and controllable, has good repeatability, the particle size of the prepared nanocapsules is 182.3±5.7 nm, the Zeta potential is-15.0±1.1 mV, and the encapsulation rate is 92.4±1.7%.

A progesterone self-emulsifying formulation, a preparation method therefor, and use thereof. The progesterone self-emulsifying formulation comprises the following preparation raw materials by mass fraction: 0.5%-20% of progesterone, 15%-50% of an oily solvent, 45%-80% of a surfactant, and 0-25% of a co-surfactant. Progesterone in the progesterone self-emulsifying formulation is in a completely dissolved state, which promotes the absorption of progesterone in the body, thereby improving the oral bioavailability of progesterone. In addition, by means of dispersing progesterone in a self-emulsifying system, under the action of an oil phase, progesterone enters the lymphatic circulation together with chylomicrons, thereby avoiding the liver first-pass effect, not only increasing the oral bioavailability of progesterone, but also reducing the plasma concentration of metabolites, and reducing the incidence of adverse reactions of oral progesterone.

The application provides a chylomicron plasma recovery treatment method, in which kaolin is modified by alkali and acid substances in sequence, and then the modified kaolin and diatomite are used to filter chylomicron plasma in sequence, and a filter with a multilayer gradient structure is used when the diatomite is used to treat chylomicron plasma; by the technical scheme, the cholesterol and triglyceride in the chylomicron plasma are significantly reduced, and a plasma product with low turbidity is obtained.

The present application relates to methods, compounds, and compositions for promoting cell COPII coagulation in a subject, modulating plasma lipids in a subject, or treating or preventing a disease, disorder, or condition associated with or caused by dyslipidemia, chyloparticle retention disease, or a symptom thereof.

The application discloses an oral drug delivery system targeting mesenteric lymph nodes, prepares a novel LNP oral delivery carrier simulating drug release of chylomicron, and explores a pathway and method of intestinal chylomicron lymphatic vessel targeting by modifying a carrier material with a targeting group. Compared with the prior art, the application can significantly improve the ability of nano-drugs to penetrate the intestinal epithelial barrier, enhance the targeting of nano-drugs, and has significant advantages in improving vaccine stability, enhancing immune response and reducing side effects through calcium alginate hydrogel wrapping.

The invention discloses a chyloleakage condition detection device in a neck lymph node cleaning operation, and relates to the technical field of medical supplies, the chyloleakage condition detection device comprises a bottom plate, and the upper side of the bottom plate is provided with a shell. According to the device for detecting the chyloleakage condition in the neck lymph node cleaning operation, liquid to be detected is actively sucked into the device through the negative pressure effect of a pressing air bag in the rapid suction and liquid homogenization assembly; the situation that the detection efficiency is reduced due to the fact that traditional detection paper is extracted only through a filter paper material in a slow passive suction mode is avoided, and meanwhile liquid to be detected in a plurality of infusion tubes flows into a plurality of liquid homogenizing grooves correspondingly formed in the upper side of a liquid homogenizing plate through corresponding liquid outlet holes in a mode that an air bag is pressed to increase the pressure intensity; the detection paper is uniformly wetted through the liquid homogenizing tank, so that the problem that the discoloration reaction is not obvious due to non-uniform wetting of the to-be-detected liquid by the traditional detection paper is prevented, and the detection accuracy is ensured.

The invention discloses an anti-Xa factor detection kit, and relates to the technical field of in vitro diagnosis. The anti-Xa factor detection kit comprises a reagent R1 and a reagent R2, the reagent R1 mainly comprises a first buffer solution, inorganic salt, a stabilizer, FXa, a first preservative, vanadate, an inhibitor and alkoxy polyethylene hydroxyl ethanol; the inhibitor is used for inhibiting the blood coagulation effect of the platelet factor 4; the reagent R2 comprises a second buffer solution, an FXa chromophoric substrate, a sugar alcohol substance and a second preservative. The anti-Xa factor detection kit provided by the invention is strong in anti-interference capability and accurate in detection, can realize pretreatment-free direct detection on chyle samples, can resist interference of interferents such as bilirubin and hemoglobin, and can meet the requirements of clinical complex sample detection.

The present application for the first time discloses a combination product of a gluten containing flour and an additive, wherein the additive comprises ascorbyl palmitate (E304i) at a concentration of between 1.1-3% of the flour weight, such as of approximately 2.2-3% of the flour weight, and Zinc at a concentration of 0.02-0.05%, such as of approximately 0.034% of the flour weight, characterized in that the consumption of the combination product does not elicit a celiac immune response towards gluten. The application further discloses a baking process for producing baked products comprising the herein described combination product and the baked products themselves, characterized in that the consumption of the baked products does not elicit a celiac immune response towards gluten in the human intestine of a celiac patient.

The invention provides a method for treating oats. The present invention relates to a process for the preparation of oat granules, comprising the following steps: a) providing oat granules, b) heat treating the oat granules at a temperature of 95-100 DEG C, c) processing the oat granules in a disc mill to obtain ground oat granules, d) sizing the ground oat granules to obtain at least one finer product component and at least one coarser product component. The technical result consists in providing an oat flour having a low alcohol soluble glutenin content, in particular a compound that causes dietary sensitivity and disorders in patients diagnosed with celiac disease. The method is suitable for large-scale production, especially because the separation is carried out in a dry state. All the oat hulls can be recycled and used for different purposes, so that any part of the oat hulls does not need to be discarded.

The invention discloses a preparation method of chylomicron, which comprises the following steps: 1) injecting Triton WR1339 into a mouse, and after a period of time, performing intragastric administration with one or more of olive oil, peanut oil and soybean oil; 2, blood is taken from eye sockets after the mice are anesthetized, and chylomicrometers.According to the method, a metabolism blocking method is adopted, the activity of lipoprotein enzyme is inhibited through Triton WR1339, meanwhile, grease intragastric administration is combined to stimulate continuous synthesis of intestinal CM, and the yield of chylomicrometerscan be obviously increased.

The present invention relates to the field of biological preparation technology, and more particularly to a kind of α-L-fucosidase detection reagent or kit and its preparation method. Which include: substrate, buffer solution with pH 4.5~5.5, metal ion chelator, inorganic compound containing metal ion, glycerol, Gemini surfactant, Tween and PEG. The present invention provides an α-L-fucosidase single reagent that improves substrate stability and resists the influence of multiple interfering substances. The single reagent can be stably stored for at least 20 months at 2-8 ° C, effectively removes the interference of multiple serum interfering substances such as bound bilirubin, free bilirubin, vitamin C, chyle and hemoglobin, and has high accuracy. Moreover, the single reagent of the present invention is convenient, simple and easy to operate, reduces the use of instrument reagent positions, and reduces detection costs.